Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp

Diabetologia

Volumn 48, Issue 3, 2005, Pages 420-426

  Hordern, S V M ^a   Wright, J E ^a   Umpleby, A M ^b   Shojaee Moradie, F ^b   Amiss, J ^a   Russell Jones, D L ^a,c  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Royal Surrey Hospital   (United Kingdom)

Author keywords

Detemir; Glucose; Insulin; Metabolism; NPH insulin

Indexed keywords

FATTY ACID; GLYCEROL; INSULIN DETEMIR; ISOPHANE INSULIN; STABLE ISOTOPE;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD SAMPLING; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG MEGADOSE; DRUG POTENCY; FEMALE; GLUCOSE ASSAY; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE HOMEOSTASIS; GLUCOSE INFUSION; HEMOCONCENTRATION; HUMAN; ISOTOPE LABELING; LIPID METABOLISM; LIPOLYSIS; LOW DRUG DOSE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

BLOOD GLUCOSE; FATTY ACIDS, NONESTERIFIED; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; HUMANS; INSULIN; INSULIN, ISOPHANE; KINETICS; LIVER; REFERENCE VALUES;

EID: 16844368165     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-005-1670-1     Document Type: Article

References (29)

1. Bolli GB (1989) The pharmacokinetic basis of insulin therapy in diabetes mellitus. Diab Res Clin Prac 6:S3-S16
2. Hildebrandt P (1991) Subcutaneous absorption of insulin in insulin dependent diabetic patients: influence of species, physico-chemical properties of insulin and physiological factors. Dan Med Bull 38:337-346
3. 125I- insulin absorption and blood glucose concentration. Diabetologia 17:291-295
4. Rosskamp RH, Park G (1999) Long acting insulin analogs. Diabetes Care 22:B109-B113
5. Havelund S, Ribel U, Plum A et al (2004) The mechanism of protraction of insulin detemir, a long acting, acylated analogue of human insulin. Diabetes 53(Suppl):P462
6. Sonksen PH, Russell-Jones D, Jones RH (1993) Growth hormone and diabetes mellitus: a review of sixty-three years of medical research and a glimpse into the future? Horm Res 40:68-79
7. Wurzburger MI, Prelevic GM, Sonksen PH, Wheeler M, Balint-Peric L (1995) Effect of recombinant human growth hormone treatment on insulin-like growth factor (IGF-I) levels in insulin-dependent diabetic patients. Acta Diabetol 32:131-134
8. Janssen JA, Lamberts SW (2000) Circulating IGF-1 and its protective role in the pathogenesis of diabetic angiopathy. Clin Endocrinol 52:1-9
9. Kruszynska YT, Home PD, Alberti KGMM (1985) Comparison of portal and peripheral insulin delivery on carbohydrate metabolism in streptozotocin- diabetic rats. Diabetologia 28:167-171
10. Brunner GA, Sendhofer G, Wutte A et al (2000) Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH in humans. Exp Clin Endocrinol Diabetes 108:100-105
11. Kurtzhals P, Havelund S, Jonassen I et al (1995) Albumin binding of insulins with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J 312:725-731
12. Ross M, Kaye GI, Pawlina W (2003) Histology a text and atlas. 4th ed. Lippincott Williams and Wilkins, Philadelphia, PA, pp 540-541
13. Gray H (1973) In: Warwick R, Williams PL (eds) Grays anatomy. 35th ed. Longman, Edinburgh, pp 1308-1309
14. Reichen J (1999) The role of the sinusoidal endothelium in liver function. News Physiol Sci 14:117-121
15. Shojaee-Moradie F, Jackson NC, Jones RH, Mallet AI, Hovorka R, Umpleby AM (1996) Quantitative measurement of 3-O methyl D glucose by gas chromatography mass spectrometry as a measure of glucose transport in vivo. J Mass Spectrom 31:961-966
16. Flakoll PJ, Zheng M, Vaughan S, Borel MJ (2000) Determination of stable isotopic enrichment and concentration of glycerol in plasma via gas chromatography-mass spectrometry for the estimation of lipolysis in vivo. J Chromatogr, B Biomed Sci Appl 744:47-54
17. Heinemann L, Sinha K, Weyer C, Loftager M, Hirsberger S, Heise T (1999) Time-action profile of the soluble fatty acid acylated long-acting insulin analogue NN304. Diabet Med 16:332-338
18. Steele R, Wall JS, DeBodo RC, Altszuler N (1956) Measurement of size and turnover rate of body glucose pool by isotope dilution method. Am J Physiol 187:15-24
19. Finegood DT, Bergman RN, Vranic M (1987) Estimation of endogenous glucose production during hyperinsulinaemic-euglycaemic glucose clamps: comparison of unlabelled and labelled exogenous glucose infusates. Diabetes 36:914-929
20. Sonksen P, Sonksen J (2000) Insulin: understanding its action in health and disease. Br J Anaesth 85:69-79
21. Wutte A, Plank J, Sinner F et al (2004) Dose-response relationship and within subject variability of insulin detemir and NPH insulin in subjects with type 1 diabetes. Diabetes 53(Suppl):P638
22. Shojaee-Moradie F, Powrie JK, Sundermann E (2000) Novel hepatoselective insulin analog: studies with a covalently linked thyroxyl-insulin complex in humans. Diabetes Care 23:1124-1129
23. Bergman RN (2000) Non-esterified fatty acids and the liver: why is insulin secreted into the portal vein? Diabetologia 43:946-952
24. Andreani D (1999) Lights and shadows of insulin treatment seen by a senior diabetologist. Exp Clin Endocrinol Diabetes 107(Suppl 2):S1-S5
25. Mayer J (1991) Bulletin of the New England Medical Center, Volume XIV, April-June 1952: the glucostatic theory of regulation of food intake and the problem of obesity (a review). Nutr Rev 49:46-48
26. Friedman MI (1995) Control of energy intake by energy metabolism. Am J Clin Nutr 62(Suppl 5):1096S-1100S
27. Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J (2004) Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther 26:724-736
28. de Leeuw I, Vague P, Selam J-L et al (2002) Lower risk of nocturnal hypoglycaemia and favourable weight development in type 1 subjects after 12 months of treatment with insulin detemir vs NPH insulin. Diabetologia 45(Suppl 2):799A
29. Vague P, Selam J-L, Skeie S et al (2003) Insulin detemir is associated with more predictable glycaemic control and lower risk of hypoglycaemia compared to NPH patients with type 1 diabetes on a basal bolus regimen with pre-meal insulin aspart. Diabetes Care 26:590-596